Acne Vulgaris Clinical Trial
Official title:
Sexual Dysfunction in Female Patients With Adult Acne Vulgaris
Assessment of sexual dysfunction in adult females with acne vulgaris and its relation to other variables as quality of life, acne severity and hormonal dysfunction.
Acne vulgaris is a common chronic inflammatory skin disease of pilosebaceous units. It is
characterized by formation of comedones, erythematous papules, pustules and less frequently
by nodules, deep pustules, or pseudocysts. In some cases, it may be accompanied by scarring.
It is the most common dermatological condition affecting adolescents worldwide. It has a
prevalence of almost 85% in people aged 12‐24 years . Women have a high prevalence than men,
especially after 25 years of age. It affects 12%-22% of women in their adult life.
Several factors are involved in the pathogenesis of the disease including abnormal sebum
production, altered follicular keratinization with subsequent follicular plugging and
Propionibacterium acnes colonization . Also, endocrine factor or androgens are considered a
major factor involved in the pathogenesis of the disease. It probably results from an
androgen excess or exacerbated response of the pilosebaceous unit to the normal circulating
androgen levels.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder to affect women in
their reproductive years. It is characterized by hyperandrogenism which results in a series
of skin changes including hirsutism, acne, seborrhea and androgenetic alopecia.
Acne vulgaris causes profound negative psychological and social effects on the quality of
life (QoL) of patients. It has a great impact on appearance which is linked with self-esteem
and self-confidence. Factors that influence the psychological impact of acne include
perceived sexual attractiveness, relationships with family and friends, judgments of others,
stigmatization, stress, and fear of scarring.
Several researches concluded that body image is an important psychological factor in women
sexual well-being. Female sexual dysfunction may associate certain dermatologic diseases as a
result of its effect on self-esteem and psychological conditions.
Despite acne vulgaris is a common disease in adult females, little is published on its effect
on female sexual function. The published studies were concerned with sexual dysfunction in
males with acne vulgaris receiving isotretinoin, females with genital acne (acne inversa) or
those with frank hormonal disturbances. None of these studies concluded whether female sexual
dysfunction is impaired with acne vulgaris as a relation to its effect on psychological
wellbeing or due to associated endocrine factors or other disease variables.
The Female Sexual Function Index (FSFI) is a widely used measurement tool to assess female
sexual function. Arabic translation of the FSFI (ArFSFI) has been validated and can be used
in the Egyptian population. It is reliable and easy to be understood by women and it is as
good as the original FSFI in assessing female sexual function.
The dermatology life quality index (DLQI) is another questionnaire that assess the impact of
dermatologic diseases on patient psychometry. It was the first dermatology-specific QOl
instrument and to date is the most commonly used.
Acne severity of the patients will be evaluated by the global acne grading system (GAGS). The
GAGS is an acne grading system developed by Doshi et al. It is a simple, accurate and fast
method for the determination of severity of acne. It requires no special equipment and is
relatively cost-effective.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
Completed |
NCT00991198 -
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
|
Phase 2 | |
Completed |
NCT01706250 -
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
|
Phase 4 |